Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.50
Bid: 60.00
Ask: 65.00
Change: -0.50 (-0.79%)
Spread: 5.00 (8.333%)
Open: 63.00
High: 63.00
Low: 62.50
Prev. Close: 63.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDS equity issue and related party transaction

12 Feb 2020 11:07

RNS Number : 7809C
NetScientific PLC
12 February 2020
 

NetScientific plc

 

("NetScientific" or the "Company")

 

PDS Biotechnology equity issue and related party transaction

 

NetScientific plc ("NetScientific", AIM:NSCI) the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) has today announced an issue of 9,230,770 new shares of common stock to raise gross proceeds of approximately US$12 million ("New Issue"), before deducting underwriting discounts, commissions and other offering expenses. The offering is expected to close on Friday, February 14, 2020, subject to customary closing conditions.

 

NetScientific currently owns 542,000 shares of PDS' common stock, representing approximately 10.28% of its undiluted share capital. The Board of NetScientific believes that PDS has strong prospects. It has therefore agreed to subscribe US$650,000 for 500,000 shares of common stock in the New Issue. Upon completion of the New Issue, NetScientific expects to own 1,042,000 shares of PDS' common stock, representing approximately 7.18% of the undiluted share capital.

 

NetScientific has cash to fund this investment, however for prudent financial management is entering into an 18 month secured £500,000 loan facility with Beckman Group. The facility, which incurs interest of 10.0% pa on drawn amounts and 3.0% pa on undrawn amounts and has an arrangement fee of 1%, can be extended by mutual agreement for an additional 6 months, and is secured on the whole of NetScientific's interest in PDS.

 

As Beckman Group is associated with M A Lawson, who is interested in 29.98 % of NetScientific's issued share capital, the secured loan facility represents a related party transaction in accordance with Rule 13 of the AIM Rules for Companies. The Directors of NetScientific consider, having consulted the Company's nominated adviser, that the terms of the facility are fair and reasonable insofar as its shareholders are concerned.

 

For more information, please contact:

NetScientific Tel: 020 3514 1800

Ian Postlethwaite, CEO and CFO

 

WH Ireland (NOMAD and Broker) Tel: 020 7220 1666

Chris Fielding / Darshan Patel

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSFLFFEESSESE
Date   Source Headline
20th Dec 201810:28 amRNSForm 8.5 - NetScientific PLC
20th Dec 20187:00 amRNSUpdate on Strategic Review
19th Dec 201811:03 amRNSForm 8.3 - NetScientific Plc
19th Dec 201811:00 amRNSForm 8.3 - NetScientific plc
19th Dec 20189:34 amRNSForm 8.5 - NetScientific PLC
18th Dec 20189:32 amRNSForm 8.5 - NetScientific PLC
13th Dec 20189:06 amRNSForm 8.5 - NetScientific PLC
7th Dec 201810:23 amRNSForm 8.5 - NetScientific PLC
5th Dec 20189:14 amRNSForm 8.5 - NetScientific PLC
4th Dec 20189:50 amRNSForm 8.5 - NetScientific PLC
3rd Dec 201810:31 amRNSForm 8.5 - NetScientific PLC
30th Nov 20183:46 pmRNSForm 8 (OPD) - NetScientific (Offeree)
30th Nov 201811:35 amRNSForm 8.5 - NetScientific PLC
29th Nov 20181:29 pmRNSForm 8.3 - NetScientific Plc
29th Nov 201812:49 pmRNSForm 8.3 - NetScientific Plc
29th Nov 201810:26 amRNSForm 8.5 - NetScientific PLC
28th Nov 20181:46 pmRNSForm 8.3 - NetScientific Plc
28th Nov 20189:51 amRNSForm 8.5 - NetScientific PLC
27th Nov 201812:44 pmGNWInvesco Ltd.: Form 8.3 - Netscientific Plc
27th Nov 201812:34 pmRNSForm 8.3 - NetScientfic Plc
27th Nov 201810:33 amRNSForm 8.5 - NetScientific PLC
27th Nov 20189:36 amRNSForm 8.3 - NetScientific PLC
26th Nov 20183:01 pmRNSAmendment to Executive Director Service Terms
26th Nov 20183:00 pmRNSAnnouncement of Strategic Review
26th Nov 201812:30 pmRNSPDS Announces Merger with Edge Therapeutics
8th Nov 20187:00 amRNSVortex Improves CTC Enumeration with Impedance
1st Nov 20187:00 amRNSVortex and STRATEC Announce Global Partnership
22nd Oct 20181:01 pmRNSGlycotest Completes $10m Series A Round with Fosun
22nd Oct 20187:00 amRNSGlycotest Completes $10m Series A Round with Fosun
28th Sep 20187:00 amRNSInterim Results
20th Sep 20187:00 amRNSProAxsis Immunoassays Selected for Large Trial
15th Aug 20187:00 amRNSWanda Launches CareLink, New Digital Health App
2nd Aug 20187:02 amRNSProAxsis Granted Third Respiratory Field CE Mark
2nd Aug 20187:00 amRNSChange of Adviser
18th Jul 20187:00 amRNSWanda Technology Enhancements
26th Jun 20184:24 pmRNSGrant of Options to Directors
21st Jun 20181:33 pmRNSResult of AGM
6th Jun 20187:00 amRNSBob Englert Appointed CEO of Vortex Biosciences
4th Jun 20187:00 amRNSProAxsis Wins Innovative Business of Year in NI
1st Jun 20187:00 amRNSProAxsis Awarded Invest NI Grant
22nd May 20184:21 pmRNSNotice of AGM and Annual Report & Accounts
21st May 20187:00 amRNSWanda Announces Significant Data with Partner HRS
2nd May 20187:00 amRNSProAxsis to Present New Data at ATS 2018
18th Apr 20185:08 pmRNSDirectors Dealing Notification
16th Apr 20182:04 pmRNSResult of General Meeting
16th Apr 20187:25 amRNSVortex to Present 2 Posters at AACR
11th Apr 201811:39 amRNSResult of Placing
3rd Apr 20184:09 pmRNSPosting of Circular
29th Mar 20187:00 amRNSProposed Placing and Subscription
29th Mar 20187:00 amRNSFull Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.